体内
雌激素受体
乳腺癌
正电子发射断层摄影术
癌症
医学
癌症研究
氟脱氧葡萄糖
雌激素
核医学
内科学
肿瘤科
生物
生物技术
作者
Antonio Aliaga,Jacques Rousseau,René Ouellette,J. Cadorette,Johan E. van Lier,Roger Lecomte,François Bénard
标识
DOI:10.1016/j.nucmedbio.2004.02.011
摘要
Different animal models of estrogen positive tumors (ER+) were evaluated for their suitability to follow tumor response after various treatment protocols, using small animal positron emission tomography (PET). ER+ human breast cancer cell lines MCF-7 and T-47D, using MDA-MB-231 as ER−; control, and murine mammary ductal carcinomas MC4-L2, MC4-L3, and MC7-L1, were compared for their in vivo growth rate and retention of ER+ status. Tumor metabolic activity was estimated from the relative uptake (% injected dose/g) of [18F]fluorodeoxyglucose (FDG) uptake, whereas ER content was determined from 16α-[18F]fluoroestradiol (FES) retention. F-18 activity values were obtained by small animal PET imaging and confirmed by tissue sampling and radioactivity counting. Reliable uptake measurements could be obtained for tumors of 200 μl or over. The human cell lines grew at a slower rate in vivo and failed to accumulate FES; in contrast, the Balb/c MC7-L1 and MC4-L2 grew well and showed good uptake of both FDG and FES. Chemotherapy and hormone therapy delayed the growth of MC7-L1 and MC4-L2 tumors, confirming their suitability as an ER+ model for therapeutic interventions. MC4-L3 tumors also showed promising results but required the presence of progestative pellets to grow. These data demonstrate that murine MC7-L1 and MC4-L2 tumors are suitable models for the monitoring of ER+ breast cancer therapy using small animal PET imaging.
科研通智能强力驱动
Strongly Powered by AbleSci AI